Immunogenicity of HIV virus-like particles in rhesus macaques by intranasal administration

Clinical and Vaccine Immunology

Volumn 19, Issue 6, 2012, Pages 970-973

  Buonaguro, Luigi ^a   Tagliamonte, Maria ^a   Visciano, Maria Luisa ^a   Andersen, Hanne ^b   Lewis, Mark ^b   Pal, Ranajit ^c   Tornesello, Maria Lina ^a   Schroeder, Ulf ^d   Hinkula, Jorma ^e   Wahren, Britta ^f   Buonaguro, Franco M ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b BIOQUAL INC   (United States)

^c ADVANCED BIOSCIENCE LABORATORIES INC   (United States)

^d KAROLINSKA INSTITUTE   (Sweden)

^e LINKÖPING UNIVERSITY   (Sweden)

^f SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; PLASMID DNA; VIRUS LIKE PARTICLE VACCINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS VIRUS LIKE PARTICLE; HUMORAL IMMUNITY; IMMUNE SYSTEM; IMMUNIZATION; IMMUNOGENICITY; MACACA; NONHUMAN; PRIORITY JOURNAL; VIRUS LIKE AGENT; VIRUS NEUTRALIZATION;

ADMINISTRATION, INTRANASAL; AIDS VACCINES; ANIMALS; BLOOD; FEMALE; HIV; HIV ANTIBODIES; INJECTIONS, INTRAMUSCULAR; MACACA MULATTA; VACCINATION; VACCINES, DNA; VACCINES, VIROSOME; VAGINA;

EID: 84861740160     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00068-12     Document Type: Article

References (44)

1. Alfsen A, Iniguez P, Bouguyon E, Bomsel M. 2001. Secretory IgA specific for a conserved epitope on gp41 envelope glycoprotein inhibits epithelial transcytosis of HIV-1. J. Immunol. 166:6257-6265. (Pubitemid 32440758)
2. Asahi-Ozaki Y, et al. 2006. Intranasal administration of adjuvantcombined recombinant influenza virus HA vaccine protects mice from the lethal H5N1 virus infection. Microbes Infect. 8:2706-2714. (Pubitemid 44692546)
3. Barnett SW, et al. 2008. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIVenvelope. AIDS 22:339-348.
4. Buonaguro L, et al. 1998. A novel gp120 sequence from an HIV-1 isolate of the A clade identified in North Uganda. AIDS Res. Hum. Retroviruses 14:1287-1289. (Pubitemid 28488940)
5. Buonaguro L, et al. 2001. High efficient production of Pr55gag virus-like particles expressing multiple HIV-1 epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A. Antiviral Res. 49: 35-47. (Pubitemid 32146577)
6. Buonaguro L, et al. 1995. Heteroduplex mobility assay and phylogenetic analysis of V3 region sequences of human immunodeficiency virus type 1 isolates from Gulu, Northern Uganda. J. Virol. 69:7971-7981.
7. Buonaguro L, et al. 2007. DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity. Vaccine 25:5968-5977. (Pubitemid 47082465)
8. Buonaguro L, et al. 2002. Induction of neutralizing antibodies and CTLs in Balb/c mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A (HIV-VLPAs). Antiviral Res. 54:189-201. (Pubitemid 34327684)
9. Buonaguro L, Tagliamonte M, Tornesello ML, Buonaguro FM. 2011. Developments in virus-like particle-based vaccines for infectious diseases and cancer. Expert Rev. Vaccines 10:1569-1583.
10. Buonaguro L, Tornesello ML, Buonaguro FM. 2010. Virus-like particles as particulate vaccines. Curr. HIV Res. 8:299-399.
11. Buonaguro L, et al. 2005. Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation. J. Virol. 79:7059-7067. (Pubitemid 40677337)
12. Burton DR, et al. 2011. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc. Natl. Acad. Sci. U. S. A. 108:11181-11186.
13. Devito C, et al. 2002. Cross-clade HIV-1-specific neutralizing IgA in mucosal and systemic compartments of HIV-1-exposed, persistently seronegative subjects. J. Acquir. Immune. Defic. Syndr. 30:413-420. (Pubitemid 34857316)
14. Devito C, et al. 2000. Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate. AIDS 14:1917-1920.
15. Devito C, et al. 2004. Intranasal HIV-1-gp160-DNA/gp41 peptide primeboost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity. J. Immunol. 173:7078-7089. (Pubitemid 39541098)
16. El-Kamary SS, et al. 2010. Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues. J. Infect. Dis. 202:1649-1658.
17. Enose Y, et al. 2002. Protection by intranasal immunization of a nefdeleted, nonpathogenic SHIV against intravaginal challenge with a heterologous pathogenic SHIV. Virology 298:306-316. (Pubitemid 35034546)
18. Guerrero RA, et al. 2001. Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosa (fecal and vaginal) immune responses. J. Virol. 75:9713-9722. (Pubitemid 32900106)
19. Haile M, et al. 2004. Immunization with heat-killed Mycobacterium bovis bacille Calmette-Guerin (BCG) in Eurocine L3 adjuvant protects against tuberculosis. Vaccine 22:1498-1508. (Pubitemid 38446928)
20. Harandi AM, Medaglini D. 2010. Mucosal adjuvants. Curr. HIV Res. 8:330-335.
21. Hinkula J, et al. 2006. A novel DNA adjuvant, N3, enhances mucosal and systemic immune responses induced by HIV-1 DNA and peptide immunizations. Vaccine 24:4494-4497. (Pubitemid 43776772)
22. Ichinohe T, et al. 2010. Intranasal administration of adjuvant-combined vaccine protects monkeys from challenge with the highly pathogenic influenza A H5N1 virus. J. Med. Virol. 82:1754-1761.
23. Kaul R, et al. 1999. HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers. AIDS 13:23-29. (Pubitemid 29078060)
24. Koopman G, et al. 2007. Comparison of intranasal with targeted lymph node immunization using PR8-Flu ISCOM adjuvanted HIV antigens in macaques. J. Med. Virol. 79:474-482. (Pubitemid 46564344)
25. Lo Caputo S, et al. 2003. Mucosal and systemic HIV-1-specific immunity in HIV-1-exposed but uninfected heterosexual men. AIDS 17:531-539. (Pubitemid 36293106)
26. Manrique M, et al. 2011. Long-term control of simian immunodeficiency virus mac251 viremia to undetectable levels in half of infected female rhesus macaques nasally vaccinated with simian immunodeficiency virus DNA/recombinant modified vaccinia virus Ankara. J. Immunol. 186:3581-3593.
27. Manrique M, et al. 2009. Nasal DNA-MVA SIV vaccination provides more significant protection from progression to AIDS than a similar intramuscular vaccination. Mucosal Immunol. 2:536-550.
28. Mazzoli S, et al. 1997. HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat. Med. 3:1250-1257. (Pubitemid 27508826)
29. Miyake A, et al. 2004. Induction of HIV-specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV-capturing nanospheres in macaques. J. Med. Virol. 73:368-377. (Pubitemid 38685742)
30. Parren PW, et al. 2001. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75:8340-8347. (Pubitemid 32743706)
31. Perrone LA, et al. 2009. Intranasal vaccination with 1918 influenza viruslike particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge. J. Virol. 83:5726-5734.
32. Petersson P, et al. 2010. The Eurocine L3 adjuvants with subunit influenza antigens induce protective immunity in mice after intranasal vaccination. Vaccine 28:6491-6497.
33. Prabakaran M, et al. 2008. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayedHAand recombinant CTB as an adjuvant. Virology 380:412-420.
34. Sedlik C, et al. 1999. Intranasal delivery of recombinant parvovirus-like particles elicits cytotoxic T-cell and neutralizing antibody responses. J. Virol. 73:2739-2744. (Pubitemid 29135659)
35. Stephenson I, et al. 2006. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. J. Virol. 80:4962-4970.
36. Tagliamonte M, et al. 2010. Constitutive expression of HIV-VLPs in stably transfected insect cell line for efficient delivery system. Vaccine 28:6417-6424.
37. Tagliamonte M, et al. 2011. HIV-Gag VLPs presenting trimeric HIV-1 gp140 spikes constitutively expressed in stable double transfected insect cell line. Vaccine 29:4913-4922.
38. Tumpey TM, Renshaw M, Clements JD, Katz JM. 2001. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J. Virol. 75:5141-5150. (Pubitemid 32448536)
39. UNAIDS. 2010. UNAIDS report on the global AIDS epidemic 2010. UNAIDS, Geneva, Switzerland. http://www.unaids.org/globalreport/Global-report.htm.
40. Veazey RS, et al. 2003. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat. Med. 9:343-346. (Pubitemid 36362791)
41. Velasquez LS, et al. 2011. Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine. Vaccine 29:5221-5231.
42. Visciano ML, et al. 2011. Generation of HIV-1 virus-like particles expressing different HIV-1 glycoproteins. Vaccine 29:4903-4912.
43. Wang BZ, et al. 2010. Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection. PLoS One 5:e13972. doi:10.1371/journal.pone.0013972.
44. Yao Q, Vuong V, Li M, Compans RW. 2002. Intranasal immunization with SIV virus-like particles (VLPs) elicits systemic and mucosal immunity. Vaccine 20:2537-2545. (Pubitemid 34615593)